Segulah Medical Acceleration Announces Investment in Quanta Dialysis Technologies
Segulah Medical Acceleration AB (SMA) a specialized growth equity investment firm focused on Medtech and related areas, announced today that it has invested in Quanta Dialysis Technologies oversubscribed and upsized $245 million Series D equity financing round. This financing is the largest ever private funding round for a dialysis device company.
“We are excited to help contribute to and support Quanta’s commitment to modernise and overhaul the outdated treatment paradigm in hemodialysis treatment, which has not seen substantial innovation for several decades” said Roger Gunnarsson, SMA’s Managing Partner.
“The SC+ system is an innovative cartridge-based invention that is compact, simple, and powerful. It is set to fundamentally change the way that dialysis care is provided, in every setting from specialized dialysis centres to acute care hospitals, and increasingly moving into the home. With this growth capital, Quanta has the resources to drive improved patient outcomes and convenience while accelerating market penetration and scale.”
The funding will allow the UK-company Quanta to scale up global operations with a focus on the United States, where SC+ received 510(k) clearance from the FDA in December for use in acute and chronic care facilities. The company is investing in significant infrastructure to scale up manufacturing, sales and customer service functions to support use in currently approved care settings within the United States, while also preparing to launch a study to support its future FDA clearance for in-home use within the United States.
“We are delighted to attract such a strong syndicate of investors, which represents a clear vote of confidence in our innovative approach to dialysis treatment,” said John E. Milad, CEO of Quanta.
“Everybody knows that dialysis care must improve. For this to happen, providers and physicians need products that allow greater flexibility to bring dialysis directly to the patient, while simplifying complexity and reducing the overall cost of care. Our small, simple-to-use, and powerful dialysis system SC+ is positioned to help transform kidney care. The funding we are announcing today will allow us to accelerate our emergence as a significant force in this market.”
The financing round was led by Glenview Capital and co-led by Novo Holdings, with support from a broad group of other top-tier investors, including BlackRock, Eldridge, Sands Capital, Millennium, Monashee Investment Management LLC., Puhua Capital, Segulah Medical Acceleration and Ancora, alongside Orlando Health, an integrated delivery network. Existing shareholders also participated in the round, including Wellington Partners, btov, Seroba Life Sciences and The Grands.
“Innovation in kidney dialysis has been stagnant for too long – but the demand from patients, doctors, health care providers and payors for new, better and more flexible solutions is impossible to ignore,” said Johan de Ruiter, Chairman of Quanta.
“We are excited to scale up our operations, enabling us to provide access to this critical new technology that will save lives, improve patients’ quality of life and lower healthcare costs.”
For more information about Segulah Medical Acceleration, please contact:
Roger Gunnarsson (email@example.com)
+46 73 850 67 32
Hemodialysis is a life sustaining treatment for patients with kidney failure to help normalize blood chemistry and remove waste products and excess fluids.
About Quanta and SC+
Quanta is enabling the future of kidney care, with a mission to bring to market solutions that improve the delivery of dialysis and help people live more freely. Headquartered in the UK and with operations in the US, Quanta is a trans-Atlantic, commercial-stage medical technology innovator.
Quanta’s lead product, SC+, is a small and simple, powerful hemodialysis system designed to provide greater freedom and flexibility in the delivery of life sustaining dialysis treatments. In the US, SC+ is FDA cleared for use in acute and chronic care facilities, and in the UK, it is CE marked, where it has been successfully used to treat patients across a range of care settings, from the ICU and the clinic to the home. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The simple-to-use and digitally connected design of SC+ is intended to empower more patients to take control of their lives with selfcare and home dialysis. Meanwhile, as a compact, portable and versatile device, SC+ provides flexibility to deliver dialysis across a wide range of use environments and prescriptions.
Learn more at Quantadt.com.
About Segulah Medical Acceleration
Segulah Medical Acceleration (SMA) is a Scandinavia-based investment company focusing on innovative medical technology companies in Europe. SMA’s objective is to help its partner companies accelerate growth and reach commercial proof of concept. SMA’s geographic remit is Scandinavia and other Western European countries. The areas within Medtech that SMA prioritizes include medical devices and consumables, diagnostics, life science tools, and digital technologies (AI). SMA has more than SEK 1.25 billion (€ 125m equivalent) in investable funds. segulahmedical.com
Segulah Medical Acceleration announces investment in Senzime2023.09.28
Segulah Medical Acceleraion AB (“SMA”) has made a commitment regarding an investment in Senzime AB (publ) (“Senzime” or “the Company”). As previously communicated in a press release from the Company, Senzime’s board of directors has resolved on a directed share issue of SEK 117 million, led by SMA together with Carnegie Fonder and existing shareholders Fjärde AP-fonden, Crafoordska Stiftelsen, Handelsbanken Fonder, Fredrik Rapp, and Swedbank Robur.Read more
Collective Minds Radiology announces closing of SEK 84m financing, led by Segulah Medical Acceleration and existing shareholders2023.08.28
Collective Minds Radiology, a fast-growing, Swedish health-tech company with a mission to build the world’s largest platform and community for healthcare collaboration, announces the closing of a SEK 84 million funding round. The round was led by Segulah Medical Acceleration (“SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, Brightly Ventures, Tradecity, Crista Galli Ventures, and several European business angels. The funding will enable Collective Minds to accelerate the commercial expansion of its professional healthcare collaboration platform for clinical consultation, education, and clinical research, with the aim of increasing the quality of care.Read more
Navinci appoints Eva Pisa as chairman, further strengthens the leadership team and establishes a Scientific Advisory Board2023.02.20
In line with the company’s vision of becoming a leader in spatial proteomics, Navinci further strengthens its organization and is pleased to announce the appointment of Dr. Eva Pisa as new chairman of the board, Dr. Caroline Gallant as new CTO and the formation of a Scientific Advisory Board chaired by Professor Ulf Landegren.Read more
Allurion to Go Public on NYSE2023.02.16
SMA portfolio company Allurion Technologies, a global leader in weight loss technology, to become publicly listed through business combinationRead more
Segulah Medical Acceleration Announces Investment in Allurion Technologies2022.09.13
Segulah Medical Acceleration AB (“SMA”) has made a minority investment in US-based Allurion Technologies during their July 2021 extension of the $34m Series D financing. The Series D round was led by Novalis LifeSciences and Romulus Capital.Read more
Segulah Medical Acceleration Announces Investment in Navinci Diagnostics2022.07.12
Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round was led by Segulah Medical Acceleration (”SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.Read more
Signifier Medical Technologies is granted HCPCS Codes2022.02.28
Signifier Medical Technologies is granted HCPCS Codes for eXciteOSA to help patients access innovative technologyRead more
Segulah Medical Acceleration Announces Investment in Signifier Medical Technologies2021.07.30
Segulah Medical Acceleration AB (SMA) announced today that it has invested in UK-based Signifier Medical Technologies’ USD 35 million Series D convertible financing. The financing was jointly led by SMA together with Angelus Venture Fund I L.P., Alan Howard (co-founder of Brevan Howard Asset Management) and Pioneer Healthcare Partners LP.Read more
Segulah Medical Acceleration Announces Investment in SAGA Diagnostics2021.06.30
Segulah Medical Acceleration AB (SMA) announced today that it has invested in cancer liquid biopsy and genomic testing company SAGA Diagnostics’ oversubscribed SEK 106 million (€10.5 million) Series A2 equity financing round. The round was led by SMA together with the Sciety investment syndicate with strong support from existing shareholders such as Hadean Ventures.Read more
Segulah Medical Acceleration Announces Investment in Quanta Dialysis Technologies2021.06.28
Segulah Medical Acceleration AB (SMA) a specialized growth equity investment firm focused on Medtech and related areas, announced today that it has invested in Quanta Dialysis Technologies oversubscribed and upsized $245 million Series D equity financing round. This financing is the largest ever private funding round for a dialysis device company.Read more
Blue chip investors back new MedTech investment company2021.04.29
Segulah Medical Acceleration, SMA, is a newly formed company specializing in medical technology investments, with a focus on Sweden, Scandinavia and Western Europe. The company is financed by leading institutions and prominent private investors, whose initial commitments amount to approximately SEK 1.2 billion.Read more